

QIAGEN NV  
Form 6-K  
November 04, 2013  
Table of Contents

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

---

FORM 6-K

---

REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16 OF  
THE SECURITIES EXCHANGE ACT OF 1934  
For the quarterly period ended September 30, 2013  
Commission File Number 0-28564

---

QIAGEN N.V.

---

Spoorstraat 50  
5911 KJ Venlo  
The Netherlands

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:  
Form 20-F  Form 40-F

Indicate by check mark whether the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T  
Rule 101(b)(1):

Indicate by check mark whether the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T  
Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby  
furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.  
Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):  
82- .

Table of Contents

QIAGEN N.V.  
Form 6-K  
TABLE OF CONTENTS

Item	Page
<u>Other Information</u>	<u>3</u>
<u>Signatures</u>	<u>4</u>
<u>Exhibit Index</u>	<u>5</u>

Table of Contents

OTHER INFORMATION

For the three- and nine-month periods ended September 30, 2013, QIAGEN N.V. prepared its quarterly report under United States generally accepted accounting principles (U.S. GAAP). This quarterly report is furnished herewith as Exhibit 99.1 and incorporated by reference herein.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

QIAGEN N.V.

BY: /S/ ROLAND SACKERS

Roland Sackers  
Chief Financial Officer

Date: November 1, 2013

Table of Contents

EXHIBIT INDEX

Exhibit Exhibit  
No.

99.1 U.S. GAAP Quarterly Report for the Period Ended September 30, 2013

5

---

Table of Contents

Exhibit 99.1

QIAGEN N.V. AND SUBSIDIARIES

U.S. GAAP QUARTERLY REPORT FOR THE PERIOD ENDED SEPTEMBER 30, 2013

TABLE OF CONTENTS

Financial Information

Condensed Consolidated Financial Statements

Condensed Consolidated Balance Sheets as of September 30, 2013 (unaudited) and December 31, 2012 2

Condensed Consolidated Statements of Income (unaudited) for the three and nine months ended September 30, 2013 and 2012 4

Condensed Consolidated Statements of Comprehensive Income (Loss) (unaudited) for the three and nine months ended September 30, 2013 and 2012 6

Condensed Consolidated Statements of Changes in Equity (unaudited) for the nine months ended September 30, 2013 and 2012 7

Condensed Consolidated Statements of Cash Flows (unaudited) for the nine months ended September 30, 2013 and 2012 8

Notes to Condensed Consolidated Financial Statements (unaudited) 9

Operating and Financial Review and Prospects 23

Quantitative and Qualitative Disclosures About Market Risk 30

Recent Authoritative Pronouncements 31

Application of Critical Accounting Policies, Judgments and Estimates 31

Off-Balance Sheet Arrangements 31

Contractual Obligations 31

Legal Proceedings 31

Risk Factors 32

Table of Contents

QIAGEN N.V. AND SUBSIDIARIES  
 CONDENSED CONSOLIDATED BALANCE SHEETS  
 (in thousands)

	Note	September 30, 2013 (unaudited)	December 31, 2012
Assets			
Current assets:			
Cash and cash equivalents		\$ 279,988	\$ 394,037
Short-term investments		75,763	90,451
Accounts receivable, net of allowance for doubtful accounts of \$9,128 and \$5,221 in 2013 and 2012, respectively		236,427	250,729
Income taxes receivable		39,494	39,150
Inventories, net	(11)	143,157	135,293
Prepaid expenses and other current assets		67,855	55,363
Deferred income taxes		31,047	27,598
Total current assets		873,731	992,621
Long-term assets:			
Property, plant and equipment, net		428,536	418,932
Goodwill	(6)	1,865,822	1,759,898
Intangible assets, net of accumulated amortization of \$589,977 and \$532,006 in 2013 and 2012, respectively	(6)	809,759	853,872
Deferred income taxes		6,415	2,323
Other assets		70,823	59,985
Total long-term assets		3,181,355	3,095,010
Total assets		\$ 4,055,086	\$ 4,087,631

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

QIAGEN N.V. AND SUBSIDIARIES  
 CONDENSED CONSOLIDATED BALANCE SHEETS  
 (in thousands, except par value)

	Note	September 30, 2013 (unaudited)	December 31, 2012
Liabilities and equity			
Current liabilities:			
Current portion of long-term debt	(9)	\$ 326	\$ 948
Accounts payable		40,098	51,311
Accrued and other liabilities (of which \$9,271 and \$7,008 due to related parties in 2013 and 2012, respectively)	(17)	243,084	196,447
Income taxes payable		16,976	14,863
Deferred income taxes		3,006	3,300
Total current liabilities		303,490	266,869
Long-term liabilities:			
Long-term debt, net of current portion (of which \$445,000 in 2013 and 2012 due to related parties)	(9) (17)	846,335	846,044
Deferred income taxes		188,690	191,609
Other liabilities		40,327	58,746
Total long-term liabilities		1,075,352	1,096,399
Commitments and contingencies	(15)		
Equity:			
Preference shares, 0.01 EUR par value, authorized—450,000 shares, no shares issued and outstanding		—	—
Financing preference shares, 0.01 EUR par value, authorized—40,000 shares, no shares issued and outstanding		—	—
Common Shares, 0.01 EUR par value, authorized—410,000 shares, issued—239,687 and 236,487 shares in 2013 and in 2012, respectively		2,812	2,769
Additional paid-in capital		1,770,609	1,718,163
Retained earnings		994,357	985,434
Accumulated other comprehensive (loss) income	(12)	1,307	43,991
Less treasury shares at cost—5,247 and 1,943 shares in 2013 and in 2012, respectively		(102,717 )	(35,653 )
Equity attributable to the owners of QIAGEN N.V.		2,666,368	2,714,704
Noncontrolling interest		9,876	9,659
Total equity		2,676,244	2,724,363
Total liabilities and equity		\$ 4,055,086	\$ 4,087,631

The accompanying notes are an integral part of these condensed consolidated financial statements.



Table of ContentsQIAGEN N.V. AND SUBSIDIARIES  
CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(in thousands, except per share data)

	Three months ended September 30,	
	2013	2012
	(unaudited)	
Net sales	\$322,111	\$304,289
Cost of sales	111,411	105,132
Gross profit	210,700	199,157
Operating expenses:		
Research and development	34,340	31,008
Sales and marketing	92,158	84,892
General and administrative, restructuring, integration and other	40,795	34,717
Acquisition-related intangible amortization	8,995	9,562
Total operating expenses	176,288	160,179
Income from operations	34,412	38,978
Other income (expense):		
Interest income	550	587
Interest expense	(7,493)	(4,967)
Other income (expense), net	2,867	(557)
Total other expense, net	(4,076)	(4,937)
Income before income taxes	30,336	34,041
Income taxes	(10,440)	4,960
Net income	40,776	29,081
Net income (loss) attributable to noncontrolling interest	75	(82)
Net income attributable to the owners of QIAGEN N.V.	\$40,701	\$29,163
Basic earnings per common share attributable to the owners of QIAGEN N.V.	\$0.17	\$0.12
Diluted earnings per common share attributable to the owners of QIAGEN N.V.	\$0.17	\$0.12
Weighted-average shares outstanding		
Basic	234,463	236,287
Diluted	242,405	242,098

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

QIAGEN N.V. AND SUBSIDIARIES  
 CONDENSED CONSOLIDATED STATEMENTS OF INCOME  
 (in thousands, except per share data)

	Nine months ended September 30,	
	2013	2012
	(unaudited)	
Net sales	\$940,899	\$907,925
Cost of sales	361,272	316,423
Gross profit	579,627	591,502
Operating expenses:		
Research and development	102,278	90,265
Sales and marketing	273,031	252,541
General and administrative, restructuring, integration and other	148,887	100,592
Acquisition-related intangible amortization	26,109	27,215
Total operating expenses	550,305	470,613
Income from operations	29,322	120,889
Other income (expense):		
Interest income	1,822	1,758
Interest expense	(22,966)	(15,122)
Other expense, net	(1,716)	(920)
Total other expense, net	(22,860)	(14,284)
Income before income taxes	6,462	106,605
Income taxes	(2,649)	15,352
Net income	9,111	91,253
Net income attributable to noncontrolling interest	188	166
Net income attributable to the owners of QIAGEN N.V.	\$8,923	\$91,087
Basic earnings per common share attributable to the owners of QIAGEN N.V.	\$0.04	\$0.39
Diluted earnings per common share attributable to the owners of QIAGEN N.V.	\$0.04	\$0.38
Weighted-average shares outstanding		
Basic	233,954	235,630
Diluted	241,438	240,405

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

## QIAGEN N.V. AND SUBSIDIARIES

## CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(in thousands)

		Three Months Ended September 30,	
	Note	2013	2012
		(unaudited)	
Net income		\$40,776	\$29,081
Losses on cash flow hedges, before tax	(7)	—	(3,226)
Reclassification adjustments on cash flow hedges, before tax	(7)	—	3,313
Cash flow hedges, before tax		—	87
Foreign currency translation adjustments, before tax		31,803	29,268
Other comprehensive income, before tax		31,803	29,355
Income tax relating to components of other comprehensive (loss) income		(263)	) 669
Total other comprehensive income, after tax		31,540	30,024
Comprehensive income		72,316	59,105
Less: Comprehensive income attributable to noncontrolling interest		373	157
Comprehensive income attributable to the owners of QIAGEN N.V.		\$71,943	\$58,948

		Nine Months Ended September 30,	
	Note	2013	2012
		(unaudited)	
Net income		\$9,111	\$91,253
Gains on cash flow hedges, before tax	(7)	—	